Last raise Oct 21, 2026, 424B3: 933K shares (23.2% of the 4.0M then)
Known so far: no new shares from the prospectus covers read · shelf room about $1.0M · not yet read: warrants, converts, options, ATM.
Shelf room
Room todayabout $1.0M, maybe lower
One third of float$1.0M ($3.1M float, Jun 30, 2025)
Sold off it, 12 monthsnothing
How this is worked out
Shelf room about $1.0M on the S-3 of Oct 9, 2026: the baby-shelf rule (public float under $75M) caps sales at one third of the $3.1M public float stated as of Jun 30, 2025, $1.0M, nothing sold off it in the last 12 months; 1 more sale off the shelf with no size read, so the room may be lower. Sources: S-3 Oct 9, 2026, effective Oct 20, 2026 · public float, as of Jun 30, 2025 · 424B3 Oct 21, 2026.
What could become new Dermata Therapeutics (DRMA) shares, from its 10-Q, 10-K, S-3 or 424B filings.
Read so far: the cover share count (4M shares, +490% from 682K on Aug 11, 2025). Not read yet: warrants, convertible notes, options and RSUs and an ATM program.Read them on EDGAR: the latest 10-Q · S-3 shelf filings.
Registrations and share actions on EDGAR (70 filings)
Registration statements, prospectuses, effectiveness notices, information statements and share sales, newest first. Showing the newest 15 of 70. Each links to the filing on EDGAR.
424B3Prospectus for shares being sold933K shares (23.2% of the 4.0M then)
S-1/AAmended registration statement; new shares or resale not read yet
S-1/AAmended registration statement; new shares or resale not read yet
S-1Registration statement; new shares or resale not read yet
Shares outstanding
4.0M
Nov 2024 to Aug 2026: from 204K to 4.0M. Adjusted for the 1-for-10 reverse split by Aug 11, 2025: each earlier count is divided by the ratio of every split after it.
From the share count on the cover of each 10-Q and 10-K, dated as each cover states.
Follow DRMA
New shelves, offerings, 10-Qs and 10-Ks from DRMA, explained in plain English when they reach EDGAR.
